BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32501190)

  • 1. ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations.
    Snyder EM; Johnson BD
    Pharmacogenomics; 2020 Jul; 21(10):695-703. PubMed ID: 32501190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
    Danser AHJ; Epstein M; Batlle D
    Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs acting on renin angiotensin system and use in ill patients with COVID-19.
    Alexandre J; Cracowski JL; Richard V; Bouhanick B;
    Therapie; 2020; 75(4):319-325. PubMed ID: 32553503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
    Tseng YH; Yang RC; Lu TS
    Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Controversy of Renin-Angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection.
    Manolis AS; Manolis TA; Manolis AA; Melita H
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):397-406. PubMed ID: 32769760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome.
    Gómez J; Albaiceta GM; García-Clemente M; López-Larrea C; Amado-Rodríguez L; Lopez-Alonso I; Hermida T; Enriquez AI; Herrero P; Melón S; Alvarez-Argüelles ME; Boga JA; Rojo-Alba S; Cuesta-Llavona E; Alvarez V; Lorca R; Coto E
    Gene; 2020 Dec; 762():145102. PubMed ID: 32882331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option?
    Şen S; Üresin AY
    Turk Kardiyol Dern Ars; 2020 Oct; 48(7):631-634. PubMed ID: 33034579
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk and prognosis of COVID-19 in patients treated with renin-angiotensin-aldosterone inhibitors.
    Vistisen ST; Bodilsen J; Scheeren TWL; Simonsen U
    Eur J Anaesthesiol; 2020 Sep; 37(9):739-742. PubMed ID: 32769503
    [No Abstract]   [Full Text] [Related]  

  • 9. [Renin Angiotensin Axis, Angiotensin Converting Enzyme 2 and Coronavirus].
    Cano F; Gajardo M; Freundlich M
    Rev Chil Pediatr; 2020 Jun; 91(3):330-338. PubMed ID: 32730512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.
    Vázquez-Cornejo E
    Bol Med Hosp Infant Mex; 2020; 77(5):274-281. PubMed ID: 33064690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists.
    Steckelings UM; Sumners C
    Clin Sci (Lond); 2020 Nov; 134(22):2987-3006. PubMed ID: 33210709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential influence of COVID-19/ACE2 on the female reproductive system.
    Jing Y; Run-Qian L; Hao-Ran W; Hao-Ran C; Ya-Bin L; Yang G; Fei C
    Mol Hum Reprod; 2020 Jun; 26(6):367-373. PubMed ID: 32365180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covid-19: the renin-angiotensin system imbalance hypothesis.
    Lanza K; Perez LG; Costa LB; Cordeiro TM; Palmeira VA; Ribeiro VT; Simões E Silva AC
    Clin Sci (Lond); 2020 Jun; 134(11):1259-1264. PubMed ID: 32507883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [ACE2 and coronavirus - a question of balance and dynamics?].
    Lundström A; Sandén P
    Lakartidningen; 2020 Apr; 117():. PubMed ID: 32314329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy.
    Bradford CN; Ely DR; Raizada MK
    Curr Hypertens Rep; 2010 Aug; 12(4):212-9. PubMed ID: 20556668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex-mediated effects of ACE2 and TMPRSS2 on the incidence and severity of COVID-19; The need for genetic implementation.
    Alshahawey M; Raslan M; Sabri N
    Curr Res Transl Med; 2020 Nov; 68(4):149-150. PubMed ID: 32917573
    [No Abstract]   [Full Text] [Related]  

  • 17. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
    Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
    Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats.
    Jessup JA; Gallagher PE; Averill DB; Brosnihan KB; Tallant EA; Chappell MC; Ferrario CM
    Am J Physiol Heart Circ Physiol; 2006 Nov; 291(5):H2166-72. PubMed ID: 16766648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].
    Sun ML; Yang JM; Sun YP; Su GH
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Mar; 43(3):219-222. PubMed ID: 32164092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
    Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
    Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.